75 related articles for article (PubMed ID: 25958230)
21. Progressive functional impairments of hippocampal neurons in a tauopathy mouse model.
Ciupek SM; Cheng J; Ali YO; Lu HC; Ji D
J Neurosci; 2015 May; 35(21):8118-31. PubMed ID: 26019329
[TBL] [Abstract][Full Text] [Related]
22. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits.
Chew J; Gendron TF; Prudencio M; Sasaguri H; Zhang YJ; Castanedes-Casey M; Lee CW; Jansen-West K; Kurti A; Murray ME; Bieniek KF; Bauer PO; Whitelaw EC; Rousseau L; Stankowski JN; Stetler C; Daughrity LM; Perkerson EA; Desaro P; Johnston A; Overstreet K; Edbauer D; Rademakers R; Boylan KB; Dickson DW; Fryer JD; Petrucelli L
Science; 2015 Jun; 348(6239):1151-4. PubMed ID: 25977373
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of status epilepticus (SE): Relationship between SE duration and subsequent development of epilepsy.
Santamarina E; Gonzalez M; Toledo M; Sueiras M; Guzman L; Rodríguez N; Quintana M; Mazuela G; Salas-Puig X
Epilepsy Behav; 2015 Aug; 49():138-40. PubMed ID: 26117525
[TBL] [Abstract][Full Text] [Related]
24. Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.
Rosén C; Farahmand B; Skillbäck T; Nägga K; Mattsson N; Kilander L; Religa D; Wimo A; Blennow K; Winblad B; Zetterberg H; Eriksdotter M
Alzheimers Dement; 2015 Dec; 11(12):1470-1479. PubMed ID: 26079415
[TBL] [Abstract][Full Text] [Related]
25. Admissions to paediatric intensive care units (PICU) with refractory convulsive status epilepticus (RCSE): A two-year multi-centre study.
Tully I; Draper ES; Lamming CR; Mattison D; Thomas C; Martland T; Appleton R
Seizure; 2015 Jul; 29():153-61. PubMed ID: 26076860
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of autophagy and tauopathy related markers in cerebral ischemia and Alzheimer's disease animal models.
Villamil-Ortiz JG; Cardona-Gomez GP
Front Aging Neurosci; 2015; 7():84. PubMed ID: 26042033
[TBL] [Abstract][Full Text] [Related]
27. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
28. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.
Soares-da-Silva P; Pires N; Bonifácio MJ; Loureiro AI; Palma N; Wright LC
Pharmacol Res Perspect; 2015 Mar; 3(2):e00124. PubMed ID: 26038700
[TBL] [Abstract][Full Text] [Related]
29. Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line.
Rubinchik-Stern M; Shmuel M; Eyal S
Epilepsia; 2015 Jul; 56(7):1023-32. PubMed ID: 26032972
[TBL] [Abstract][Full Text] [Related]
30. Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Chakrabarty P; Hudson VJ; Sacino AN; Brooks MM; D'Alton S; Lewis J; Golde TE; Giasson BI
Acta Neuropathol; 2015 Aug; 130(2):303-5. PubMed ID: 25982997
[No Abstract] [Full Text] [Related]
31. Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid.
Tsai SY; Pokrass MJ; Klauer NR; Nohara H; Su TP
Proc Natl Acad Sci U S A; 2015 May; 112(21):6742-7. PubMed ID: 25964330
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid and blood biomarkers of status epilepticus.
Hanin A; Lambrecq V; Denis JA; Imbert-Bismut F; Rucheton B; Lamari F; Bonnefont-Rousselot D; Demeret S; Navarro V
Epilepsia; 2020 Jan; 61(1):6-18. PubMed ID: 31828792
[TBL] [Abstract][Full Text] [Related]
33. Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer's disease, and epilepsy.
Martin SP; Leeman-Markowski BA
Front Neurol; 2023; 14():1287545. PubMed ID: 38249745
[TBL] [Abstract][Full Text] [Related]
34. Fluid Biomarkers of Neuro-Glial Injury in Human Status Epilepticus: A Systematic Review.
Giovannini G; Meletti S
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569895
[TBL] [Abstract][Full Text] [Related]
35. Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.
Negi D; Granak S; Shorter S; O'Leary VB; Rektor I; Ovsepian SV
Neurotherapeutics; 2023 Apr; 20(3):767-778. PubMed ID: 36884195
[TBL] [Abstract][Full Text] [Related]
36. Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms.
Hwang K; Vaknalli RN; Addo-Osafo K; Vicente M; Vossel K
Front Aging Neurosci; 2022; 14():903973. PubMed ID: 35923547
[TBL] [Abstract][Full Text] [Related]
37. Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus.
Giovannini G; Bedin R; Ferraro D; Vaudano AE; Mandrioli J; Meletti S
Epilepsia; 2022 Jan; 63(1):e23-e29. PubMed ID: 34806176
[TBL] [Abstract][Full Text] [Related]
38. Markers in Status Epilepticus Prognosis.
Alkhachroum A; Der-Nigoghossian CA; Rubinos C; Claassen J
J Clin Neurophysiol; 2020 Sep; 37(5):422-428. PubMed ID: 32890064
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes and treatments effectiveness in status epilepticus resolved by antiepileptic drugs: A five-year observational study.
Orlandi N; Giovannini G; Rossi J; Cioclu MC; Meletti S
Epilepsia Open; 2020 Jun; 5(2):166-175. PubMed ID: 32524042
[TBL] [Abstract][Full Text] [Related]
40. Neurodegenerative pathways as targets for acquired epilepsy therapy development.
Casillas-Espinosa PM; Ali I; O'Brien TJ
Epilepsia Open; 2020 Jun; 5(2):138-154. PubMed ID: 32524040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
